|
|
|
| Clinical Study of Dupilumab Injection Combined with Crisaborole in Adults with Moderate to Severe Atopic Dermatitis |
| HE Xiaoyu, MA Hong, WU Wei |
| First-author's address: Affiliated Hospital of Jiangsu University, Zhenjiang 212001, China |
|
|
|
|
Abstract Objective: To explore the clinical effect of Dupilumab Injection combined with Crisaborole in adults with moderate to severe atopic dermatitis. Method: A total of 102 adults with moderate to severe atopic dermatitis admitted to Affiliated Hospital of Jiangsu University from May 2021 to May 2022 were selected and divided into routine group and observation group by random number table method, with 51 cases in each group. The routine group was treated with Dupilumab Injection, while the observation group was treated with Dupilumab Injection combined with Crisaborole. The clinical efficacy and the changes of investigator global assessment (IGA) score, eczema area and severity index (EASI) score, eosinophils (EOS) and immunoglobulin E (IgE) before and after treatment were compared between the two groups, and the occurrence of adverse reactions in the two groups during treatment was analyzed. Result: The total effective rate of the observation group was higher than that of the routine group (P<0.05). Before treatment, there were no statistically significant differences in the IGA and EASI scores between the two groups (P>0.05); after treatment, the IGA and EASI scores of both groups were lower than those before treatment (P<0.05), while the IGA and EASI scores of the observation group were lower (P<0.05). Before treatment, there were no statistically significant differences in the levels of IgE and EOS between the two groups (P>0.05); after treatment, IgE and EOS in both groups decreased compared to before treatment (P<0.05), while in the observation group, they were both lower (P<0.05). During the treatment period, there was 1 case of local redness and swelling, 1 case of conjunctivitis in the routine group, 1 case of conjunctivitis and 2 cases of pain in multiple interphalangeal joints in both hands in the observation group, there was no statistically significant difference in the total incidence of adverse reactions between the two groups (字2=0.210, P=0.647). Conclusion: The combination of Dupilumab Injection and Crisaborole in the treatment of adult moderate to severe atopic dermatitis can enhance the therapeutic effect, alleviate the patient's condition, reduce IgE and EOS levels, and have good drug safety.
|
|
Received: 19 July 2023
|
|
|
|
|
|
|
